CGRP and migraine: from bench to bedside

Migraine treatment has reached a new era with the development of drugs that target the trigeminal neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. The CGRP related therapies offer considerable improvements over existing drugs as they are the first to be designed to act on the tri...

Full description

Saved in:
Bibliographic Details
Published in:Revue neurologique Vol. 177; no. 7; pp. 785 - 790
Main Author: Edvinsson, L.
Format: Journal Article
Language:English
Published: France Elsevier Masson SAS 01.09.2021
Subjects:
Calcitonin
Calcitonin Gene-Related Peptide
Calcitonin Gene-Related Peptide Receptor Antagonists - therapeutic use
CGRP
CLR
CTR
Humans
Migraine Disorders - drug therapy
RAMPs
Receptors
Receptors, Calcitonin Gene-Related Peptide
CTR
CLR
Receptors
RAMPs
CGRP
ISSN:0035-3787
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Migraine treatment has reached a new era with the development of drugs that target the trigeminal neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. The CGRP related therapies offer considerable improvements over existing drugs as they are the first to be designed to act on the trigeminal pain system, more specific and with few adverse events. Small molecule CGRP receptor antagonists, such as rimegepant and ubrogepant, are effective for the acute treatment of migraine headache. In contrast, monoclonal antibodies against CGRP or the CGRP receptor are beneficial for the prophylactic treatments in chronic migraine. Here I will provide a historical overview of the long path that led to their successful development. In addition, I will discuss aspects on the biology of CGRP signalling, the role of CGRP in migraine headache, the efficacy of CGRP targeted treatment, and synthesize what currently is known about the role of CGRP in the trigeminovascular system.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0035-3787
DOI:10.1016/j.neurol.2021.06.003